Immunovia announces collaboration with Lund University Diabetes Centre for the early detection of pancreatic cancer in diabetes risk group
LUND, Sweden ― Immunovia AB is delighted to announce a collaboration with the researchers at Lund University Diabetes Centre (LUDC) to validate the company´s biomarker signature in high risk group of newly-onset type 2 diabetics (NoD) patients over the age of 50. The risk of these patients to develop pancreatic cancer is over 8 times greater than that of the general population.The collaboration is designed as a retrospective validation study, in which LUDC, a consortium of research groups at Lund University, will deliver blood samples from NoD patients who subsequently developed pancreatic